Wells Fargo & Company Ascendis Pharma A/S Transaction History

Wells Fargo & Company

$407 Billion
Q2 2024

A detailed history of Wells Fargo & Company transactions in Ascendis Pharma A/S stock. As of the latest transaction made, Wells Fargo & Company holds 10,610 shares of ASND stock, worth $1.27 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

10,610

Previous 11,061 4.08%

Holding current value

$1.27 Million

Previous $1.67 Million 13.52%

% of portfolio

0.0%

Previous 0.0%

18 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	SELL	$121.07 - $153.67 $54,602 - $69,305	-451 Reduced 4.08%	10,610 $1.45 Million
Q1 2024 May 10, 2024	BUY	$123.45 - $159.4 $73,576 - $95,002	596 Added 5.7%	11,061 $1.67 Million
Q4 2023 Feb 09, 2024	BUY	$86.1 - $127.36 $45,633 - $67,500	530 Added 5.33%	10,465 $1.32 Million
Q3 2023 Nov 13, 2023	SELL	$86.5 - $103.97 $76,466 - $91,909	-884 Reduced 8.17%	9,935 $930,000
Q2 2023 Aug 15, 2023	BUY	$69.96 - $97.84 $6,086 - $8,512	87 Added 0.81%	10,819 $965,000
Q1 2023 May 12, 2023	SELL	$104.9 - $126.78 $2,937 - $3,549	-28 Reduced 0.26%	10,732 $1.15 Million
Q4 2022 Feb 13, 2023	BUY	$99.42 - $131.97 $150,323 - $199,538	1,512 Added 16.35%	10,760 $1.31 Million
Q3 2022 Nov 14, 2022	SELL	$84.03 - $110.23 $31,343 - $41,115	-373 Reduced 3.88%	9,248 $954,000
Q2 2022 Aug 12, 2022	SELL	$78.08 - $117.61 $4.08 Million - $6.15 Million	-52,281 Reduced 84.46%	9,621 $895,000
Q1 2022 May 16, 2022	BUY	$102.18 - $135.75 $439,987 - $584,539	4,306 Added 7.48%	61,902 $7.26 Million
Q4 2021 Feb 14, 2022	SELL	$127.1 - $169.66 $36.7 Million - $48.9 Million	-288,445 Reduced 83.36%	57,596 $7.75 Million
Q3 2021 Nov 15, 2021	BUY	$112.67 - $176.92 $37.7 Million - $59.2 Million	334,782 Added 2973.46%	346,041 $55.2 Million
Q2 2021 Aug 16, 2021	BUY	$121.62 - $145.29 $374,832 - $447,783	3,082 Added 37.69%	11,259 $1.48 Million
Q1 2021 May 13, 2021	BUY	$124.92 - $173.33 $602,489 - $835,970	4,823 Added 143.8%	8,177 $1.05 Million
Q4 2020 Feb 09, 2021	BUY	$151.2 - $182.76 $67,284 - $81,328	445 Added 15.3%	3,354 $559,000
Q3 2020 Nov 05, 2020	SELL	$134.29 - $154.32 $141,004 - $162,036	-1,050 Reduced 26.52%	2,909 $449,000
Q2 2020 Aug 13, 2020	SELL	$110.87 - $156.01 $227,283 - $319,820	-2,050 Reduced 34.12%	3,959 $585,000
Q1 2020 May 14, 2020	BUY	$97.01 - $145.11 $582,933 - $871,965	6,009 New	6,009 $677,000

Others Institutions Holding ASND

# of Institutions

223

Shares Held

56.5M

Call Options Held

142K

Put Options Held

259K

View Full List

About Ascendis Pharma A/S

Ticker ASND
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,810,200
Market Cap $6.65B
Description
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult h...

More about ASND

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

News

Stay updated on Wells Fargo & Company with notifications on news.

Account

Wells Fargo & Company Ascendis Pharma A/S Transaction History